

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6271358		2001-08-07	Manoharan et al.	
	2	6166197		2000-12-26	Cook et al.	
	3	6127533		2000-10-03	Cook et al.	
	4	6054299		2000-04-25	Conrad	
	5	5998203		1999-12-07	Matulic-Adamic et al.	
	6	5587361		1996-12-24	Cook et al.	
	7	5521302		1996-05-28	Cook	
	8	5328470		1994-07-12	Nabel et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

9	5212295		1993-05-18	Cook	
10	4980286		1990-12-25	Morgan et al.	
11	4868116		1989-09-19	Morgan et al.	
12	6573046		2003-06-03	Kmiec et al.	
13	5939262		1999-08-17	Pasloske et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040072779		2004-04-15	Kreutzer et al.	
	2	20040001811		2004-01-01	Kreutzer et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ;	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	-----------------------------	------------------------	------------------	-------------------------------------------------	------------------------------------------------------------------------	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10612179
Filing Date		2003-07-02
First Named Inventor	ROLAND KREUTZER	
Art Unit	1635	
Examiner Name	TRACY ANN VIVLEMORE	
Attorney Docket Number	A2038-706120	

1	2005/012357	WO		2005-02-10	Milmer et al.		<input type="checkbox"/>
2	2004/065601	WO		2004-08-05	Philipp et al.		<input type="checkbox"/>
3	2004/045543	WO		2004-06-03	Dharmacon, Inc		<input type="checkbox"/>
4	2004/027030	WO		2004-04-01	Isis Pharmaceuticals, Inc.		<input type="checkbox"/>
5	2004/015107	WO		2004-02-19	Giese et al.		<input type="checkbox"/>
6	2001/36646	WO		2008-08-27	Zernicka-Goetz et al.		<input type="checkbox"/>
7	2000/22113	WO		2000-04-20	Skillern et al.		<input type="checkbox"/>
8	2000/22114	WO		2000-04-20	Conrad		<input type="checkbox"/>
9	1999/54459	WO		1999-10-28	Thompson et al.		<input type="checkbox"/>
10	1992/07573	WO		1992-05-14	Rafield et al.		<input type="checkbox"/>
11	1989/07136	WO		1989-08-10	Wilson et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

12	1989/05345	WO		1989-06-15	Wilson et al.		<input type="checkbox"/>
13	1989/02468	WO		1989-03-23	Mulligan et al.		<input type="checkbox"/>
14	9927444.1	GB		1999-11-19	Zernicka-Goetz et al.		<input type="checkbox"/>
15	102 35 620.3	DE		2002-08-02			<input checked="" type="checkbox"/>
16	101 00 586	DE		2002-04-11	Ribopharma AG		<input checked="" type="checkbox"/>
17	19618797	DE		1996-10-05	Wolf Bertling		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ARMENTANO ET AL., "Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B" Proc. Natl. Acad. Sci. USA 87:6141-6145 (1990).	<input type="checkbox"/>
	2	Auszug aus der online-Rolle des EPA.	<input type="checkbox"/>
	3	BASBAUM ET AL., "Focalized proteolysis: spatial and temporal regulation of extra cellular matrix degradation at the cell surface" Curr. Opin. Cell Biol. 8:731-738 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

4	BECK, "Unknotting the Complexities of Multidrug Resistance: The Involvement of DNA Topoisomerases in Drug Action and Resistance" J. Natl. Cancer Inst. 81:1683-1685 (1989).	<input type="checkbox"/>
5	BERKNER ET AL., "Development of Adenovirus Vectors for the Expression of Heterologous Genes" BioTechniques 6 (7):616-629 (1998).	<input type="checkbox"/>
6	BIRKEDAL-HANSEN ET AL., "Matrix Metalloproteinases: A Review" Crit. Rev. Oral Biol. Med. 4:197-250 (1993).	<input type="checkbox"/>
7	BOYD, "Invasion and metastasis" Cancer Metastasis Rev. 15:77-89 (1996).	<input type="checkbox"/>
8	BRAASCH ET AL., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA" Chem. Biol. 8:1-7 (2001).	<input type="checkbox"/>
9	BRINCKERHOFF ET AL., "Matrix metalloproteinases: a tail of a frog that became a prince" Nature Reviews 3:207-214 (2002).	<input type="checkbox"/>
10	BUCCHINI ET AL., "Pancreatic Expression of Human Insulin Gene in Transgenic Mice" PNAS USA 83:2511-2515 (1986).	<input type="checkbox"/>
11	CHAO ET AL., "BCL-2 FAMILY: Regulators of Cell Death" Annu. Rev. Immunol. 16:395-419 (1998).	<input type="checkbox"/>
12	CHEN ET AL., "Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo" Proc. Natl. Acad. Sci. USA 91:3054-3057 (1994).	<input type="checkbox"/>
13	CHILDS ET AL., "The MDR Superfamily of Genes and Its Biological Implications" Imp. Adv. Oncol. 21-36 (1994).	<input type="checkbox"/>
14	CHOWDHURY ET AL., "Long-Term Improvement of Hypercholesterolemia After Ex Vivo Gene Therapy in LDLR-Deficient Rabbits" Science 254:1802-1805 (1991).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

15	CIOCA ET AL., "RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines" Cancer Gene Therapy 10:125-133 (2003).	<input type="checkbox"/>
16	COLE ET AL., "Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line" Science 258:1650-1654 (1992).	<input type="checkbox"/>
17	CONE ET AL., "High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range" Proc. Natl. Acad. Sci. USA 81:6349-6353 (1984).	<input type="checkbox"/>
18	COOK, "Medicinal chemistry of antisense oligonucleotides - future opportunities" Anti-Cancer Drug Design 6:585-607 (1991).	<input type="checkbox"/>
19	CORNETTA ET AL., "Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans" Human Gene Therapy 2(1):5-14 (1991).	<input type="checkbox"/>
20	COUTURE ET AL., "Anti-gene therapy: the use of ribozymes to inhibit gene function: Trends in Genetics," 12:510-515 (1996).	<input type="checkbox"/>
21	CROOKE ET AL., "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in Mice" J. Pharmacol. Exp. Ther. 277:923-937 (1996).	<input type="checkbox"/>
22	DAI ET AL., "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo" Proc. Natl. Acad. Sci. USA 89:10892-10895 (1992).	<input type="checkbox"/>
23	DANOS ET AL., "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges" Proc. Natl. Acad. Sci. USA 85:6460-6464 (1988).	<input type="checkbox"/>
24	D'Ari, "Cycle-regulated genes and cell cycle regulation" Bioassays 23:563-565 (2001).	<input type="checkbox"/>
25	DELGADO ET AL., "The Uses and Properties of PEG-Linked Proteins" Crit. Rev. Therap. Drug Carrier Sys. 9:249-304 (1992).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

26	Diagramm zur Illustrierung des Gegenstands des angegriffenen Patents.	<input type="checkbox"/>
27	Diagramm zur Illustrierung der Offenbarung von D5.	<input type="checkbox"/>
28	Diagramm zur Illustrierung der Offenbarung von D13.	<input type="checkbox"/>
29	DOCHERTY ET AL., "Nutrient regulation of insulin gene expression" FASEB J. 8:20-27 (1994).	<input type="checkbox"/>
30	EDER ET AL., "Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation" Leukemia 13:1383-1389 (1999).	<input type="checkbox"/>
31	EGLITIS ET AL., "Gene Expression in Mice After High Efficiency Retroviral-Mediated Gene Transfer" Science 230:1395-1398 (1985).	<input type="checkbox"/>
32	ERIKSSON ET AL., "Establishment and characterization of mouse strain (TLL) that spontaneously develops T-cell lymphomas/leukemia" Exp. Hematol. 27:682-688 (1999).	<input type="checkbox"/>
33	FAN ET AL., "Reversal of Multidrug Resistance in Cancer", ed. Kellen, CRC, Boca Raton, FL, pp. 93-125.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.